# Proteinuric Kidney Disease FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/proteinuric-kidney-disease

> 2 upcoming FDA catalysts in proteinuric Kidney Disease: VX-147 (VRTX) on Jun to Sep 2028 (topline data readout); VX-147 (VRTX) on June 2028 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 20, 2026 | [Inaxaplin primary completion](https://sec-api.dev/pdufa/inaxaplin) | VRTX | Proteinuric Kidney Disease | completed | "NCT06794996 (Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-07-20 (ACTUAL); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06794996)) |
| September 2026 | [MZE829 primary completion](https://sec-api.dev/pdufa/mze829) | MAZE | Proteinuric Kidney Disease | delayed | "NCT06830629 (A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor Maze Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06830629)) |
| Sep to Dec 2026 | [MZE829 topline data readout](https://sec-api.dev/pdufa/mze829) | MAZE | Proteinuric Kidney Disease | scheduled | "NCT06830629 (A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor Maze Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06830629)) |
| Jun to Sep 2028 | [VX-147 topline data readout](https://sec-api.dev/pdufa/vx-147) | VRTX | Proteinuric Kidney Disease | scheduled | "NCT05312879 (Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-06-02 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05312879)) |
| June 2028 | [VX-147 primary completion](https://sec-api.dev/pdufa/vx-147) | VRTX | Proteinuric Kidney Disease | scheduled | "NCT05312879 (Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-06-02 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05312879)) |

## Drugs

- [Inaxaplin](https://sec-api.dev/pdufa/inaxaplin) (VRTX)
- [MZE829](https://sec-api.dev/pdufa/mze829) (MAZE)
- [VX-147](https://sec-api.dev/pdufa/vx-147) (VRTX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/proteinuric-kidney-disease.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Proteinuric Kidney Disease FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/proteinuric-kidney-disease

```bibtex
@misc{secapidev_indications_proteinuric_kidney_disease_20261116,
  title        = {Proteinuric Kidney Disease FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/proteinuric-kidney-disease}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_proteinuric_kidney_disease_20261116","title":"Proteinuric Kidney Disease FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/proteinuric-kidney-disease","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
